Nov. 10, 2010, 8:00 a.m. EST
Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From
U.S. Department of Treasury
Covers Therapeutic Applications of Two Technology Platforms
PHILADELPHIA, Nov 10, 2010 (GlobeNewswire via COMTEX) -- Hemispherx
Biopharma, Inc. /quotes/comstock/14*!heb/quotes/nls/heb (HEB 0.50,
-.00, -0.44%) announced today grant awards totaling $488,958 from the
U.S. Department of Treasury in support of its Ampligen(R) and
Alferon(R) development programs. These awards were approved by the
Internal Revenue Service (IRS), in conjunction with the Department of
Heath and Human Services (DHHS), under the Qualifying Therapeutic
Discovery Project Program, established under the Patient Protection
and Affordable Care Act of 2010 for projects that showed significant
potential to produce new and cost-saving therapies, support jobs and
increase U.S. competitiveness. The amounts granted for these two
Hemispherx projects were for the maximum per-project amount set by the
IRS based on the limited amount of funds allocated for the program.
The Hemispherx Alferon(R) program grant application was based on the
potential to show Alferon N Injection(R), an FDA-approved treatment
for refractory HPV, and Alferon(R) LDO (low dose oral), an
experimental formulation, to be an efficacious and inexpensive
preventative or treatment for seasonal and pandemic flu.
The Hemispherx Ampligen(R) grant application was based on the
continuing development of Ampligen(R) (an experimental therapeutic
with broad spectrum antiviral properties) in clinical programs in
Chronic Fatigue Syndrome, (CFS) and as an adjuvant for seasonal /
pandemic influenza vaccines and cancer immunotherapy.
Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From
U.S. Department of Treasury
Covers Therapeutic Applications of Two Technology Platforms
PHILADELPHIA, Nov 10, 2010 (GlobeNewswire via COMTEX) -- Hemispherx
Biopharma, Inc. /quotes/comstock/14*!heb/quotes/nls/heb (HEB 0.50,
-.00, -0.44%) announced today grant awards totaling $488,958 from the
U.S. Department of Treasury in support of its Ampligen(R) and
Alferon(R) development programs. These awards were approved by the
Internal Revenue Service (IRS), in conjunction with the Department of
Heath and Human Services (DHHS), under the Qualifying Therapeutic
Discovery Project Program, established under the Patient Protection
and Affordable Care Act of 2010 for projects that showed significant
potential to produce new and cost-saving therapies, support jobs and
increase U.S. competitiveness. The amounts granted for these two
Hemispherx projects were for the maximum per-project amount set by the
IRS based on the limited amount of funds allocated for the program.
The Hemispherx Alferon(R) program grant application was based on the
potential to show Alferon N Injection(R), an FDA-approved treatment
for refractory HPV, and Alferon(R) LDO (low dose oral), an
experimental formulation, to be an efficacious and inexpensive
preventative or treatment for seasonal and pandemic flu.
The Hemispherx Ampligen(R) grant application was based on the
continuing development of Ampligen(R) (an experimental therapeutic
with broad spectrum antiviral properties) in clinical programs in
Chronic Fatigue Syndrome, (CFS) and as an adjuvant for seasonal /
pandemic influenza vaccines and cancer immunotherapy.